Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison Article Swipe

PDF

Josep‐María Ribera , Thibaud Prawitz , Andreas Freitag , Anuj Sharma , Balázs Dobi , Federica Rizzo , Lorenzo Sabatelli , Petros Patos ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1007/s12325-023-02497-y

Related Topics

Acute Myeloid Leukemia

Concepts

Medicine Imatinib Ponatinib Internal medicine Oncology Vincristine Hazard ratio Chemotherapy Cyclophosphamide Confidence interval Dasatinib Myeloid leukemia

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1007/s12325-023-02497-y
PDF: https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf
OA Status: hybrid
Cited By: 13
References: 50
Related Works: 10
OpenAlex ID: https://openalex.org/W4377116108

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4377116108

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1007/s12325-023-02497-y

Digital Object Identifier
Title: Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-05-19

Full publication date if available
Authors: Josep‐María Ribera, Thibaud Prawitz, Andreas Freitag, Anuj Sharma, Balázs Dobi, Federica Rizzo, Lorenzo Sabatelli, Petros Patos

List of authors in order
Landing page: https://doi.org/10.1007/s12325-023-02497-y

Publisher landing page
PDF URL: https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: hybrid

Open access status per OpenAlex
OA URL: https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf

Direct OA link when available
Concepts: Medicine, Imatinib, Ponatinib, Internal medicine, Oncology, Vincristine, Hazard ratio, Chemotherapy, Cyclophosphamide, Confidence interval, Dasatinib, Myeloid leukemia

Top concepts (fields/topics) attached by OpenAlex
Cited by: 13

Total citation count in OpenAlex
Citations by year (recent): 2025: 7, 2024: 5, 2023: 1

Per-year citation counts (last 5 years)
References (count): 50

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4377116108
doi	https://doi.org/10.1007/s12325-023-02497-y
ids.doi	https://doi.org/10.1007/s12325-023-02497-y
ids.pmid	https://pubmed.ncbi.nlm.nih.gov/37208556
ids.openalex	https://openalex.org/W4377116108
fwci	5.07184756
mesh[0].qualifier_ui
mesh[0].descriptor_ui	D000328
mesh[0].is_major_topic	False
mesh[0].qualifier_name
mesh[0].descriptor_name	Adult
mesh[1].qualifier_ui
mesh[1].descriptor_ui	D006801
mesh[1].is_major_topic	False
mesh[1].qualifier_name
mesh[1].descriptor_name	Humans
mesh[2].qualifier_ui	Q000627
mesh[2].descriptor_ui	D000068877
mesh[2].is_major_topic	False
mesh[2].qualifier_name	therapeutic use
mesh[2].descriptor_name	Imatinib Mesylate
mesh[3].qualifier_ui
mesh[3].descriptor_ui	D010677
mesh[3].is_major_topic	True
mesh[3].qualifier_name
mesh[3].descriptor_name	Philadelphia Chromosome
mesh[4].qualifier_ui	Q000188
mesh[4].descriptor_ui	D054198
mesh[4].is_major_topic	True
mesh[4].qualifier_name	drug therapy
mesh[4].descriptor_name	Precursor Cell Lymphoblastic Leukemia-Lymphoma
mesh[5].qualifier_ui	Q000627
mesh[5].descriptor_ui	D003520
mesh[5].is_major_topic	False
mesh[5].qualifier_name	therapeutic use
mesh[5].descriptor_name	Cyclophosphamide
mesh[6].qualifier_ui	Q000627
mesh[6].descriptor_ui	D000971
mesh[6].is_major_topic	False
mesh[6].qualifier_name	therapeutic use
mesh[6].descriptor_name	Antineoplastic Combined Chemotherapy Protocols
mesh[7].qualifier_ui	Q000627
mesh[7].descriptor_ui	D003907
mesh[7].is_major_topic	False
mesh[7].qualifier_name	therapeutic use
mesh[7].descriptor_name	Dexamethasone
mesh[8].qualifier_ui
mesh[8].descriptor_ui	D000328
mesh[8].is_major_topic	False
mesh[8].qualifier_name
mesh[8].descriptor_name	Adult
mesh[9].qualifier_ui
mesh[9].descriptor_ui	D006801
mesh[9].is_major_topic	False
mesh[9].qualifier_name
mesh[9].descriptor_name	Humans
mesh[10].qualifier_ui	Q000627
mesh[10].descriptor_ui	D000068877
mesh[10].is_major_topic	False
mesh[10].qualifier_name	therapeutic use
mesh[10].descriptor_name	Imatinib Mesylate
mesh[11].qualifier_ui
mesh[11].descriptor_ui	D010677
mesh[11].is_major_topic	True
mesh[11].qualifier_name
mesh[11].descriptor_name	Philadelphia Chromosome
mesh[12].qualifier_ui	Q000188
mesh[12].descriptor_ui	D054198
mesh[12].is_major_topic	True
mesh[12].qualifier_name	drug therapy
mesh[12].descriptor_name	Precursor Cell Lymphoblastic Leukemia-Lymphoma
mesh[13].qualifier_ui	Q000627
mesh[13].descriptor_ui	D003520
mesh[13].is_major_topic	False
mesh[13].qualifier_name	therapeutic use
mesh[13].descriptor_name	Cyclophosphamide
mesh[14].qualifier_ui	Q000627
mesh[14].descriptor_ui	D000971
mesh[14].is_major_topic	False
mesh[14].qualifier_name	therapeutic use
mesh[14].descriptor_name	Antineoplastic Combined Chemotherapy Protocols
mesh[15].qualifier_ui	Q000627
mesh[15].descriptor_ui	D003907
mesh[15].is_major_topic	False
mesh[15].qualifier_name	therapeutic use
mesh[15].descriptor_name	Dexamethasone
type	article
title	Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
biblio.issue	7
biblio.volume	40
biblio.last_page	3103
biblio.first_page	3087
grants[0].funder	https://openalex.org/F4320317544
grants[0].award_id
grants[0].funder_display_name	Incyte
topics[0].id	https://openalex.org/T11215
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9998999834060669
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2720
topics[0].subfield.display_name	Hematology
topics[0].display_name	Chronic Myeloid Leukemia Treatments
topics[1].id	https://openalex.org/T10950
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9983999729156494
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2739
topics[1].subfield.display_name	Public Health, Environmental and Occupational Health
topics[1].display_name	Acute Lymphoblastic Leukemia research
topics[2].id	https://openalex.org/T11157
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.984000027179718
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2716
topics[2].subfield.display_name	Genetics
topics[2].display_name	Chronic Lymphocytic Leukemia Research
funders[0].id	https://openalex.org/F4320317544
funders[0].ror	https://ror.org/00cvzzg84
funders[0].display_name	Incyte
is_xpac	False
apc_list.value	3390
apc_list.currency	EUR
apc_list.value_usd	4390
apc_paid.value	3390
apc_paid.currency	EUR
apc_paid.value_usd	4390
concepts[0].id	https://openalex.org/C71924100
concepts[0].level	0
concepts[0].score	0.8945768475532532
concepts[0].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[0].display_name	Medicine
concepts[1].id	https://openalex.org/C2777583451
concepts[1].level	3
concepts[1].score	0.7940428256988525
concepts[1].wikidata	https://www.wikidata.org/wiki/Q177094
concepts[1].display_name	Imatinib
concepts[2].id	https://openalex.org/C2780381907
concepts[2].level	5
concepts[2].score	0.7927813529968262
concepts[2].wikidata	https://www.wikidata.org/wiki/Q198728
concepts[2].display_name	Ponatinib
concepts[3].id	https://openalex.org/C126322002
concepts[3].level	1
concepts[3].score	0.6933983564376831
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[3].display_name	Internal medicine
concepts[4].id	https://openalex.org/C143998085
concepts[4].level	1
concepts[4].score	0.6103509664535522
concepts[4].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[4].display_name	Oncology
concepts[5].id	https://openalex.org/C2779429289
concepts[5].level	4
concepts[5].score	0.5111480355262756
concepts[5].wikidata	https://www.wikidata.org/wiki/Q408977
concepts[5].display_name	Vincristine
concepts[6].id	https://openalex.org/C207103383
concepts[6].level	3
concepts[6].score	0.42083296179771423
concepts[6].wikidata	https://www.wikidata.org/wiki/Q3930246
concepts[6].display_name	Hazard ratio
concepts[7].id	https://openalex.org/C2776694085
concepts[7].level	2
concepts[7].score	0.29988032579421997
concepts[7].wikidata	https://www.wikidata.org/wiki/Q974135
concepts[7].display_name	Chemotherapy
concepts[8].id	https://openalex.org/C2776755627
concepts[8].level	3
concepts[8].score	0.28630489110946655
concepts[8].wikidata	https://www.wikidata.org/wiki/Q408524
concepts[8].display_name	Cyclophosphamide
concepts[9].id	https://openalex.org/C44249647
concepts[9].level	2
concepts[9].score	0.2723536491394043
concepts[9].wikidata	https://www.wikidata.org/wiki/Q208498
concepts[9].display_name	Confidence interval
concepts[10].id	https://openalex.org/C2779536868
concepts[10].level	4
concepts[10].score	0.19288116693496704
concepts[10].wikidata	https://www.wikidata.org/wiki/Q419940
concepts[10].display_name	Dasatinib
concepts[11].id	https://openalex.org/C2778729363
concepts[11].level	2
concepts[11].score	0.18092548847198486
concepts[11].wikidata	https://www.wikidata.org/wiki/Q11688946
concepts[11].display_name	Myeloid leukemia
keywords[0].id	https://openalex.org/keywords/medicine
keywords[0].score	0.8945768475532532
keywords[0].display_name	Medicine
keywords[1].id	https://openalex.org/keywords/imatinib
keywords[1].score	0.7940428256988525
keywords[1].display_name	Imatinib
keywords[2].id	https://openalex.org/keywords/ponatinib
keywords[2].score	0.7927813529968262
keywords[2].display_name	Ponatinib
keywords[3].id	https://openalex.org/keywords/internal-medicine
keywords[3].score	0.6933983564376831
keywords[3].display_name	Internal medicine
keywords[4].id	https://openalex.org/keywords/oncology
keywords[4].score	0.6103509664535522
keywords[4].display_name	Oncology
keywords[5].id	https://openalex.org/keywords/vincristine
keywords[5].score	0.5111480355262756
keywords[5].display_name	Vincristine
keywords[6].id	https://openalex.org/keywords/hazard-ratio
keywords[6].score	0.42083296179771423
keywords[6].display_name	Hazard ratio
keywords[7].id	https://openalex.org/keywords/chemotherapy
keywords[7].score	0.29988032579421997
keywords[7].display_name	Chemotherapy
keywords[8].id	https://openalex.org/keywords/cyclophosphamide
keywords[8].score	0.28630489110946655
keywords[8].display_name	Cyclophosphamide
keywords[9].id	https://openalex.org/keywords/confidence-interval
keywords[9].score	0.2723536491394043
keywords[9].display_name	Confidence interval
keywords[10].id	https://openalex.org/keywords/dasatinib
keywords[10].score	0.19288116693496704
keywords[10].display_name	Dasatinib
keywords[11].id	https://openalex.org/keywords/myeloid-leukemia
keywords[11].score	0.18092548847198486
keywords[11].display_name	Myeloid leukemia
language	en
locations[0].id	doi:10.1007/s12325-023-02497-y
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S27230875
locations[0].source.issn	0741-238X, 1865-8652
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	0741-238X
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Advances in Therapy
locations[0].source.host_organization	https://openalex.org/P4310320330
locations[0].source.host_organization_name	Adis, Springer Healthcare
locations[0].source.host_organization_lineage	https://openalex.org/P4310320330
locations[0].license	cc-by-nc
locations[0].pdf_url	https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by-nc
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Advances in Therapy
locations[0].landing_page_url	https://doi.org/10.1007/s12325-023-02497-y
locations[1].id	pmid:37208556
locations[1].is_oa	False
locations[1].source.id	https://openalex.org/S4306525036
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	PubMed
locations[1].source.host_organization	https://openalex.org/I1299303238
locations[1].source.host_organization_name	National Institutes of Health
locations[1].source.host_organization_lineage	https://openalex.org/I1299303238
locations[1].license
locations[1].pdf_url
locations[1].version	publishedVersion
locations[1].raw_type
locations[1].license_id
locations[1].is_accepted	True
locations[1].is_published	True
locations[1].raw_source_name	Advances in therapy
locations[1].landing_page_url	https://pubmed.ncbi.nlm.nih.gov/37208556
locations[2].id	pmh:oai:pubmedcentral.nih.gov:10272268
locations[2].is_oa	True
locations[2].source.id	https://openalex.org/S2764455111
locations[2].source.issn
locations[2].source.type	repository
locations[2].source.is_oa	False
locations[2].source.issn_l
locations[2].source.is_core	False
locations[2].source.is_in_doaj	False
locations[2].source.display_name	PubMed Central
locations[2].source.host_organization	https://openalex.org/I1299303238
locations[2].source.host_organization_name	National Institutes of Health
locations[2].source.host_organization_lineage	https://openalex.org/I1299303238
locations[2].license	cc-by-nc
locations[2].pdf_url	https://pmc.ncbi.nlm.nih.gov/articles/PMC10272268/pdf/12325_2023_Article_2497.pdf
locations[2].version	submittedVersion
locations[2].raw_type	Text
locations[2].license_id	https://openalex.org/licenses/cc-by-nc
locations[2].is_accepted	False
locations[2].is_published	False
locations[2].raw_source_name	Adv Ther
locations[2].landing_page_url	https://www.ncbi.nlm.nih.gov/pmc/articles/10272268
locations[3].id	pmh:oai:ddd.uab.cat:289226
locations[3].is_oa	True
locations[3].source.id	https://openalex.org/S4306400380
locations[3].source.issn
locations[3].source.type	repository
locations[3].source.is_oa	False
locations[3].source.issn_l
locations[3].source.is_core	False
locations[3].source.is_in_doaj	False
locations[3].source.display_name	Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)
locations[3].source.host_organization	https://openalex.org/I123044942
locations[3].source.host_organization_name	Universitat Autònoma de Barcelona
locations[3].source.host_organization_lineage	https://openalex.org/I123044942
locations[3].license	cc-by-nc
locations[3].pdf_url
locations[3].version	submittedVersion
locations[3].raw_type	Article
locations[3].license_id	https://openalex.org/licenses/cc-by-nc
locations[3].is_accepted	False
locations[3].is_published	False
locations[3].raw_source_name
locations[3].landing_page_url	https://ddd.uab.cat/record/289226
indexed_in	crossref, pubmed
authorships[0].author.id	https://openalex.org/A5084354003
authorships[0].author.orcid	https://orcid.org/0000-0003-1042-6024
authorships[0].author.display_name	Josep‐María Ribera
authorships[0].countries	ES
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210089592
authorships[0].affiliations[0].raw_affiliation_string	ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, c/ Canyet, s/n, 08916, Badalona, Spain
authorships[0].institutions[0].id	https://openalex.org/I4210089592
authorships[0].institutions[0].ror	https://ror.org/00btzwk36
authorships[0].institutions[0].type	facility
authorships[0].institutions[0].lineage	https://openalex.org/I4210089592, https://openalex.org/I4210144824, https://openalex.org/I4387153040
authorships[0].institutions[0].country_code	ES
authorships[0].institutions[0].display_name	Josep Carreras Leukaemia Research Institute
authorships[0].author_position	first
authorships[0].raw_author_name	Josep-Maria Ribera
authorships[0].is_corresponding	True
authorships[0].raw_affiliation_strings	ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, c/ Canyet, s/n, 08916, Badalona, Spain
authorships[1].author.id	https://openalex.org/A5003280863
authorships[1].author.orcid
authorships[1].author.display_name	Thibaud Prawitz
authorships[1].affiliations[0].raw_affiliation_string	Evidera Inc., Paris, France
authorships[1].author_position	middle
authorships[1].raw_author_name	Thibaud Prawitz
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Evidera Inc., Paris, France
authorships[2].author.id	https://openalex.org/A5029656810
authorships[2].author.orcid	https://orcid.org/0000-0003-0265-9338
authorships[2].author.display_name	Andreas Freitag
authorships[2].countries	GB
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210130100
authorships[2].affiliations[0].raw_affiliation_string	Evidera Inc., London, UK
authorships[2].institutions[0].id	https://openalex.org/I4210130100
authorships[2].institutions[0].ror	https://ror.org/02gv1pt92
authorships[2].institutions[0].type	company
authorships[2].institutions[0].lineage	https://openalex.org/I4210130100
authorships[2].institutions[0].country_code	GB
authorships[2].institutions[0].display_name	EVRAZ (United Kingdom)
authorships[2].author_position	middle
authorships[2].raw_author_name	Andreas Freitag
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Evidera Inc., London, UK
authorships[3].author.id	https://openalex.org/A5100715857
authorships[3].author.orcid	https://orcid.org/0000-0002-8240-0539
authorships[3].author.display_name	Anuj Sharma
authorships[3].affiliations[0].raw_affiliation_string	Evidera Inc., Montreal, Canada
authorships[3].author_position	middle
authorships[3].raw_author_name	Anuj Sharma
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Evidera Inc., Montreal, Canada
authorships[4].author.id	https://openalex.org/A5053599584
authorships[4].author.orcid	https://orcid.org/0000-0002-1187-4104
authorships[4].author.display_name	Balázs Dobi
authorships[4].affiliations[0].raw_affiliation_string	Evidera Inc., Budapest, Hungary
authorships[4].author_position	middle
authorships[4].raw_author_name	Balázs Dobi
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Evidera Inc., Budapest, Hungary
authorships[5].author.id	https://openalex.org/A5018289974
authorships[5].author.orcid	https://orcid.org/0000-0002-5945-8222
authorships[5].author.display_name	Federica Rizzo
authorships[5].affiliations[0].raw_affiliation_string	Incyte Biosciences International Sàrl, Morges, Switzerland
authorships[5].author_position	middle
authorships[5].raw_author_name	Federica Rizzo
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Incyte Biosciences International Sàrl, Morges, Switzerland
authorships[6].author.id	https://openalex.org/A5070517090
authorships[6].author.orcid	https://orcid.org/0000-0001-7373-9306
authorships[6].author.display_name	Lorenzo Sabatelli
authorships[6].affiliations[0].raw_affiliation_string	Incyte Biosciences International Sàrl, Morges, Switzerland
authorships[6].author_position	middle
authorships[6].raw_author_name	Lorenzo Sabatelli
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Incyte Biosciences International Sàrl, Morges, Switzerland
authorships[7].author.id	https://openalex.org/A5089601231
authorships[7].author.orcid
authorships[7].author.display_name	Petros Patos
authorships[7].affiliations[0].raw_affiliation_string	Incyte Biosciences International Sàrl, Morges, Switzerland
authorships[7].author_position	last
authorships[7].raw_author_name	Petros Patos
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	Incyte Biosciences International Sàrl, Morges, Switzerland
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf
open_access.oa_status	hybrid
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11215
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9998999834060669
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2720
primary_topic.subfield.display_name	Hematology
primary_topic.display_name	Chronic Myeloid Leukemia Treatments
related_works	https://openalex.org/W2979771750, https://openalex.org/W3041254650, https://openalex.org/W3088102054, https://openalex.org/W2013496366, https://openalex.org/W2970398182, https://openalex.org/W2110257339, https://openalex.org/W3130148693, https://openalex.org/W3009090025, https://openalex.org/W2761936011, https://openalex.org/W388027184
cited_by_count	13
counts_by_year[0].year	2025
counts_by_year[0].cited_by_count	7
counts_by_year[1].year	2024
counts_by_year[1].cited_by_count	5
counts_by_year[2].year	2023
counts_by_year[2].cited_by_count	1
locations_count	4
best_oa_location.id	doi:10.1007/s12325-023-02497-y
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S27230875
best_oa_location.source.issn	0741-238X, 1865-8652
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	0741-238X
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Advances in Therapy
best_oa_location.source.host_organization	https://openalex.org/P4310320330
best_oa_location.source.host_organization_name	Adis, Springer Healthcare
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320330
best_oa_location.license	cc-by-nc
best_oa_location.pdf_url	https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by-nc
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Advances in Therapy
best_oa_location.landing_page_url	https://doi.org/10.1007/s12325-023-02497-y
primary_location.id	doi:10.1007/s12325-023-02497-y
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S27230875
primary_location.source.issn	0741-238X, 1865-8652
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	0741-238X
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Advances in Therapy
primary_location.source.host_organization	https://openalex.org/P4310320330
primary_location.source.host_organization_name	Adis, Springer Healthcare
primary_location.source.host_organization_lineage	https://openalex.org/P4310320330
primary_location.license	cc-by-nc
primary_location.pdf_url	https://link.springer.com/content/pdf/10.1007/s12325-023-02497-y.pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by-nc
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Advances in Therapy
primary_location.landing_page_url	https://doi.org/10.1007/s12325-023-02497-y
publication_date	2023-05-19
publication_year	2023
referenced_works	https://openalex.org/W2178307116, https://openalex.org/W2054481710, https://openalex.org/W2105908490, https://openalex.org/W1558827591, https://openalex.org/W4230048554, https://openalex.org/W2123940645, https://openalex.org/W2060833726, https://openalex.org/W2403017780, https://openalex.org/W2023111945, https://openalex.org/W2030796837, https://openalex.org/W1931165463, https://openalex.org/W1506738181, https://openalex.org/W1838408716, https://openalex.org/W1972060994, https://openalex.org/W2509076190, https://openalex.org/W2329186770, https://openalex.org/W2147109509, https://openalex.org/W2483008971, https://openalex.org/W2902317207, https://openalex.org/W2104694028, https://openalex.org/W2008001245, https://openalex.org/W2790692615, https://openalex.org/W3093938683, https://openalex.org/W3097687160, https://openalex.org/W4308057391, https://openalex.org/W3205544897, https://openalex.org/W2092901728, https://openalex.org/W2970684805, https://openalex.org/W2650689221, https://openalex.org/W1982967337, https://openalex.org/W2089360398, https://openalex.org/W2139499066, https://openalex.org/W2099616647, https://openalex.org/W2162801973, https://openalex.org/W2000116184, https://openalex.org/W2135492799, https://openalex.org/W2036724262, https://openalex.org/W2033862877, https://openalex.org/W2102929198, https://openalex.org/W2105098746, https://openalex.org/W2802056043, https://openalex.org/W2153701773, https://openalex.org/W2148854558, https://openalex.org/W2620151596, https://openalex.org/W2940834643, https://openalex.org/W2108322312, https://openalex.org/W2087090648, https://openalex.org/W3161074857, https://openalex.org/W4282924465, https://openalex.org/W191574092
referenced_works_count	50
abstract_inverted_index
cited_by_percentile_year.max	99
cited_by_percentile_year.min	89
corresponding_author_ids	https://openalex.org/A5084354003
countries_distinct_count	2
institutions_distinct_count	8
corresponding_institution_ids	https://openalex.org/I4210089592
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.7300000190734863
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.94783198
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	True